Cardiotoxicity Associated with Targeted Therapies in Lung Cancer: A Retrospective Cohort Study of 2,427 Patients at Renji Hospital

Authors:

Zhixuan Zhang [a,b]*

*Corresponding authors

Affiliations:

[a]Department of Cardiology, State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

[b]Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.

The authors declare no potential conflicts of interest.

Abstract

Background:

Targeted therapies are widely used in lung cancer, yet their cardiotoxic effects in real-world populations remain insufficiently characterized. Comparative risk across therapeutic classes and the temporal evolution of biomarker-defined injury remain unclear.

Methods:

We conducted a retrospective cohort study of 2,427 patients with lung malignancies treated with 82 targeted agents at Renji Hospital (2018–2024). Cardiotoxicity was defined as any new elevation in cardiac biomarkers according to the 2022 ESC cardio-oncology guideline criteria, assessed after treatment initiation. Multivariable Cox models estimated cardiotoxicity risk across drug classes. Restricted cubic splines characterized nonlinear associations between PD-1 inhibitor exposure frequency and cardiotoxicity. Longitudinal cardiac biomarker trajectories were evaluated using generalized additive mixed models.

Results:

Among 2,069 analyzable patients, 326 (15.8%) developed cardiotoxicity. Patients with cardiotoxicity had a higher burden of baseline cardiovascular comorbidities. After adjustment for demographic and clinical covariates, PD-1 inhibitors demonstrated the highest cardiotoxicity risk (HR 1.81, 95% CI 1.43–2.28), while VEGF inhibitors also increased risk (HR 1.33, 95% CI 1.06–1.67). EGFR inhibitor use was associated with a lower incidence of cardiotoxicity (HR 0.61, 95% CI 0.48–0.78). A nonlinear relationship was observed between PD-1 administration frequency and cardiotoxicity, with risk increasing steeply up to approximately four treatment cycles. Longitudinal analyses showed distinct exposure-related divergence in B-type natriuretic peptide (BNP) and creatine kinase-MB (CK-MB) trajectories among PD-1–treated patients, whereas troponin remained largely stable.

Conclusions:

In this large real-world cohort, PD-1 inhibitors were independently associated with elevated cardiotoxicity risk, with a cycle-dependent pattern peaking early in treatment. BNP and CK-MB provided sensitive indicators of evolving myocardial stress during PD-1 therapy. These findings highlight the need for exposure-specific and target-specific cardiac surveillance strategies in lung cancer patients undergoing targeted therapy.

Introduction

Lung cancer remains the leading cause of cancer-related death worldwide (1). Over the past decade, substantial progress in early detection and treatment has been achieved through advances in molecularly targeted and translational research (1). The introduction of targeted agents such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor (VEGF) inhibitors, and immune checkpoint inhibitors particularly programmed death-1 (PD-1) antibodies has transformed the therapeutic landscape, substantially improving progression-free and overall survival (2). However, as survival improves and treatment duration extends, cardiovascular toxicities have become increasingly recognized as important adverse effects that may offset therapeutic benefits and affect long-term outcomes (3).

Cardiotoxicity in the context of targeted therapy encompasses a wide spectrum of manifestations, ranging from asymptomatic elevations in cardiac biomarkers to clinically significant heart failure, arrhythmias, and vascular events (3). The underlying mechanisms are diverse, involving direct myocardial injury (4), endothelial dysfunction (5), and immune-mediated inflammation (6). Previous studies have reported that PD-1 inhibitors can trigger myocarditis, pericardial disease, and biomarker-defined myocardial injury (7), whereas VEGF inhibition may induce hypertension, thrombosis, and heart failure (8). Conversely, EGFR inhibitors have been associated with a relatively low incidence of cardiotoxicity, though cases of thromboembolic events, heart failure, cardiomyopathy, arrhythmia, and hypertension have been reported (9).

Nonetheless, most available data arise from small case series or clinical trial populations with stringent inclusion criteria, limiting their generalizability to real-world patients who often present with advanced age, comorbidities, and polypharmacy (10). Real-world evidence on the comparative cardiotoxic profiles of different targeted therapies in lung cancer remains scarce (11). Furthermore, the temporal evolution of cardiac biomarkers in patients exposed to immune checkpoint inhibitors is not well characterized, and the cumulative risk associated with repeated drug administration is poorly defined (12). Given the growing use of PD-1–based regimens and combinations in clinical oncology, understanding the dose–response and temporal dynamics of cardiotoxicity is of immediate clinical relevance.

In this retrospective cohort study, we comprehensively evaluated 2,427 lung cancer patients treated with 82 targeted agents at Renji Hospital over a six-year period. We aimed to quantify the incidence of cardiotoxicity,

identify associated demographic and clinical risk factors, and compare the cardiotoxic risk among major targeted therapy classes. In addition, we explored nonlinear associations between PD-1 inhibitor exposure frequency and cardiotoxicity risk and modeled longitudinal trajectories of cardiac biomarkers to elucidate distinct temporal patterns of cardiac response. This study provides a detailed, data-driven framework for individualized cardiac monitoring in targeted therapy recipients.

Methods

Study Design and Population

We conducted a retrospective cohort study including all patients diagnosed with lung malignancies (ICD-10: C34) who received at least one targeted agent at Renji Hospital between January 1, 2018, and June 26, 2024. A total of 2,427 eligible patients were identified after data cleaning (Figure 1).

Patients lacking any cardiac biomarker measurements—creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP), troponin I (TnI), or high-sensitivity troponin I (hs-TnI) were excluded (n = 358), yielding a final analytical cohort of 2,069 individuals.

Cardiotoxicity was defined as a new elevation in any of the aforementioned cardiac biomarkers following initiation of targeted therapy. The cohort was stratified into patients with cardiotoxicity (n = 326, 15.8%) and without cardiotoxicity (n = 1,743, 84.2%).

The primary analysis compared the risk of cardiotoxicity across major targeted therapy classes (EGFR, PD-1, VEGF, ALK, and others) using multivariable Cox proportional hazards models adjusted for age, sex, and cardiovascular comorbidities.

The secondary analyses included (a) subgroup analyses by demographic and clinical characteristics, (b) assessment of nonlinear associations between PD-1 inhibitor administration frequency and cardiotoxicity risk using restricted cubic spline models, and (c) evaluation of longitudinal trajectories of cardiac biomarkers via generalized additive mixed models (GAMMs) stratified by PD-1 exposure status.

The follow-up period (days from treatment initiation to the first cardiotoxicity event or end of follow-up) was calculated for each patient.

Definition of Cardiotoxicity

Cardiotoxicity was defined as any new elevation in cardiac biomarkers—troponin I (> 0.04 ng/mL), high-sensitivity troponin (> 0.04 ng/mL), BNP (> 100 pg/mL), CK-MB (> 6.3 ng/mL), or NT-proBNP (> 20 pg/mL)—occurring on or after the first administration of a targeted drug. Cases were further classified per the 2022 ESC cardio-oncology guideline into:

(1) symptomatic CTRCD (heart failure requiring hospitalization or advanced therapy);

(2) asymptomatic CTRCD (biomarker elevation only);

(3) vascular toxicity;

(4) hypertension; and

(5) arrhythmia.

Drug Classification

Eighty-two targeted agents were grouped by their primary molecular targets (EGFR, PD-1, VEGF, ALK, BCR-ABL, HER2, and others; see Supplementary Table 1). Binary exposure variables (yes/no) were created for each target. Drug exposure frequency was calculated as the total number of administration orders documented by treating oncologists.

Covariates

Baseline variables included age, sex, and pre-existing cardiovascular and metabolic comorbidities diagnosed before initiation of targeted therapy. Comorbidities were identified using International Classification of Diseases, 10th Revision (ICD-10) codes, and only the earliest diagnosis date was recorded for each condition. Specifically, hypertension was defined by codes I10–I13 and I15 (including hypertensive crisis I16 when applicable). Coronary artery disease and myocardial infarction were identified by I20–I25. Arrhythmias and conduction disorders were defined by I44–I45, I47–I49. Heart failure and cardiomyopathy were captured by I50 and I42 (including drug-induced or secondary cardiomyopathy I42.7), with I51.7 (left ventricular hypertrophy) included when relevant. Thrombotic, atherosclerotic, and cerebrovascular disorders were identified using I26, I61–I64, I65–I67.2, I70–I71, I80–I83, I87.1–I87.2, and I81–I82, encompassing pulmonary embolism, stroke, peripheral arterial disease, and venous thromboembolism. Pulmonary hypertension was defined as I27.2, and valvular heart disease by I34–I37. Diabetes mellitus and dyslipidemia were identified using E10–E14 and E78, respectively.

Statistical Analysis

Continuous variables were compared using *t*-tests or Wilcoxon rank-sum tests as appropriate. Categorical variables were analyzed using chi-square tests. Associations between drug exposure and cardiotoxicity were evaluated with multivariable Cox proportional hazards models adjusted for demographic and clinical covariates. Nonlinear dose–response relationships were modeled with restricted cubic spline (RCS) functions. Analyses were performed in R, with two-sided $P < 0.05$ considered significant.

Statistical Modeling of Longitudinal Biomarker Trajectories

We used **generalized additive mixed models (GAMMs)** to evaluate longitudinal trajectories of cardiac biomarkers following treatment initiation, stratified by PD-1 inhibitor exposure status. Biomarkers with sufficient longitudinal data (≥30 observations from ≥5 patients) were included in the analysis.

Model specification:

- **Dependent variable**: Log-transformed biomarker levels [log (value + 1)] to normalize distributions
- **Primary predictor**: Time since treatment initiation (continuous, in days) with exposure-specific smooth functions using penalized thin plate regression splines (k = 8 basis functions)
- **Stratification variable**: PD-1 inhibitor exposure status (exposed vs. unexposed)
- **Covariates**: Sex, age, and cumulative PD-1 treatment duration
- **Random effects**: Patient-level intercepts to account for within-subject correlation

Models were fitted using the bam() function with fast restricted maximum likelihood (fREML) estimation from the mgcv package in R (version 4.3.1). Predicted biomarker levels with 95% confidence intervals were generated at median covariate values across a grid of time points spanning the observed follow-up period (0–2500 days).

We focused on four cardiac biomarkers with established clinical relevance for cardiotoxicity surveillance: B-type natriuretic peptide (BNP), creatine kinase-MB (CK-MB), myoglobin, and troponin.

Results

Baseline Characteristics

All baseline demographic, clinical, and treatment characteristics for both groups are summarized in Table 1.

Of the 2,069 patients included in the analysis, 326 (15.8%) developed cardiotoxicity after targeted therapy.

The non-toxicity group comprised 1,743 patients, and the cardiotoxicity group comprised 326 patients. The median follow-up period was 527 days (IQR 192–974). The mean age did not differ significantly between groups ($p = 0.096$). Cardiotoxicity was more common in males (67.8% vs. 61.6%, $p = 0.038$).

Pre-existing cardiovascular comorbidities were significantly more prevalent among patients who developed cardiotoxicity, including hypertension (37.7% vs. 19.4%, $p < 0.001$), myocardial infarction (11.0% vs. 3.1%, $p < 0.001$), arrhythmia (7.7% vs. 2.6%, $p < 0.001$), heart failure (4.9% vs. 0.7%, $p < 0.001$), and diabetes (15.0% vs. 10.2%, $p = 0.014$). No significant differences were observed in the baseline prevalence of hyperlipidemia or thrombosis.

In terms of oncological treatment, patients in the cardiotoxicity group were more likely to receive PD-1 inhibitors (40.5% vs. 30.1%, $p < 0.001$) and VEGF inhibitors (54.0% vs. 41.3%, $p < 0.001$), whereas EGFR inhibitor use was lower (34.0% vs. 43.1%, $p = 0.003$).

The cardiotoxicity group also received a higher median number of treatment administrations, including PD-1 inhibitors (5.5 vs. 3.0, $p < 0.001$), EGFR inhibitors (17.0 vs. 7.0, $p < 0.001$), VEGF inhibitors (5.0 vs. 4.0, $p = 0.002$), ALK inhibitors (14.0 vs. 6.0, $p = 0.002$), and other targeted agents (5.0 vs. 2.0, $p < 0.001$).

Monitoring of cardiac biomarkers was significantly more frequent in patients who developed cardiotoxicity (all $p < 0.001$). Testing rates were higher for BNP (99.4% vs. 85.5%), CK-MB (98.5% vs. 91.2%), Myoglobin (96.3% vs. 78.9%), and Troponin (94.5% vs. 83.1%), with similar trends observed for hs-TnT (43.6% vs. 19.5%) and NT-proBNP (39.3% vs. 19.9%).

Among those tested, the median number of biomarker assessments was also significantly higher in the cardiotoxicity group (all $p < 0.003$), particularly for CK-MB (10.0 [IQR 6.0–17.0] vs. 4.0 [IQR 2.0–9.0], $p < 0.001$), BNP (8.0 [IQR 4.0–15.0] vs. 3.0 [IQR 1.0–6.0], $p < 0.001$), hs-TnT (8.0 [IQR 4.0–16.8] vs. 4.0 [IQR 2.0–9.0], $p < 0.001$), Troponin (6.0 [IQR 3.0–10.0] vs. 2.0 [IQR 1.0–5.0], $p < 0.001$), and Myoglobin (6.5 [IQR 4.0–12.0] vs. 3.0 [IQR 1.0–6.0], $p < 0.001$).

Drug Class Associations

Multivariable Cox regression analysis was performed to evaluate the association between specific targeted therapies and the risk of cardiotoxicity, adjusting for age, gender, and baseline cardiovascular comorbidities

(including hypertension, myocardial infarction, arrhythmia, heart failure, thrombosis, diabetes, and hyperlipidemia) (Figure 2A).

After adjustment, PD-1 inhibitor use was associated with the highest risk of cardiotoxicity (HR = 1.81, 95% CI 1.43–2.28), followed by Other targeted therapy (HR = 1.71, 95% CI 1.24–2.36), VEGF inhibitors (HR = 1.33, 95% CI 1.06–1.67), and ALK inhibitors (HR = 1.38, 95% CI 0.85–2.22). In contrast, EGFR inhibitor use was associated with a significantly lower risk of cardiotoxicity (HR = 0.61, 95% CI 0.48–0.78).

Subgroup analysis revealed heterogeneous treatment effects across different targeted therapies and patient characteristics (Figure 2B). For PD-1 inhibitors, increased cardiovascular risk was consistently observed across most subgroups (all P<0.01), except in patients aged <65 years (HR 1.38, 95% CI 0.87-2.18, P=0.18). A significant interaction was detected between age and PD-1 therapy (P for interaction=0.03), with older patients (≥65 years) demonstrating higher risk (HR 2.39, 95% CI 1.81-3.16) compared to younger patients. In contrast, EGFR inhibitors consistently showed protective cardiovascular effects across all subgroups examined, with hazard ratios ranging from 0.47 to 0.61 (all P<0.01), without significant effect modification by any patient characteristics (all P for interaction >0.05).

VEGF inhibitors demonstrated increased cardiovascular risk in most subgroups, though the effect was not significant among patients with pre-existing CVD history (HR 1.18, 95% CI 0.85-1.65, P=0.32). For other targeted agents, a significant interaction with comorbidity burden was observed (P for interaction <0.01), with the highest risk noted in patients without comorbidities (HR 2.76, 95% CI 1.81-4.19, P<0.01). Additionally, cardiovascular history significantly modified the effect of other targeted therapies (P for interaction=0.02), with attenuated risk observed in patients with pre-existing CVD (HR 1.35, 95% CI 0.78-2.36, P=0.29) compared to those without CVD history (HR 2.68, 95% CI 1.80-3.99, P<0.01).

Non-linear association between the number of PD-1 administrations and cardiotoxicity risk

Restricted cubic spline analysis demonstrated a significant non-linear association between the number of PD-1 administrations and cardiotoxicity risk (Figure 3, P for nonlinearity = 0.002). Risk rose rapidly up to ~4 administrations (HR at 4 ≈ 2.0, 95% CI ≈ 1.50–2.65), then increased more slowly thereafter, indicating attenuation of the marginal risk at higher exposure counts.

Temporal Trajectories of Cardiac Biomarkers by PD-1 Exposure

Figure 4 shows the modeled longitudinal trajectories of four cardiac biomarkers according to PD-1 inhibitor exposure over a follow-up of up to 2500 days after treatment initiation. All generalized additive models

converged with satisfactory fit.

For BNP, PD-1–exposed patients displayed a distinct late-phase rise, with both groups remaining stable around 50 pg/mL during the first 1500 days, after which the exposed group showed an exponential increase exceeding 200 pg/mL by day 2500, whereas the unexposed group maintained levels around 50–100 pg/mL. CK-MB levels increased gradually in both groups, with a steeper slope in the PD-1–exposed group emerging by ~1000 days and becoming more pronounced after 1500 days, reaching 4 ng/mL by day 2500 versus 3.5 ng/mL in the unexposed group. Myoglobin followed a similar pattern to BNP, remaining stable until about 1500 days, then rising sharply in the exposed group to over 75 ng/mL by day 2500, compared with decreases to around 25 ng/mL in the unexposed group. In contrast, troponin trajectories were largely comparable between groups, showing only minor fluctuations (1.05 → 1.10 ng/mL in exposed; 1.10 → 1.00 ng/mL in unexposed) with overlapping confidence intervals throughout the follow-up. Overall, BNP and myoglobin exhibited the most pronounced delayed elevations in the PD-1–exposed cohort, suggesting potential cumulative cardiotoxic effects associated with prolonged PD-1 inhibitor exposure, whereas CK-MB showed moderate sensitivity and troponin remained largely stable.

Comparison of temporal trajectories between PD-1–treated and untreated groups

Temporal trajectories of cardiac biomarkers were compared between PD-1–exposed and unexposed patients using generalized additive mixed models including smooth time-by-exposure interaction terms (Table 2). All models were adjusted for age, sex, PD-1 administration frequency, and seven cardiovascular comorbidities (myocardial infarction, hypertension, arrhythmia, thrombosis, diabetes, hyperlipidemia, and heart failure). Model comparison by likelihood ratio tests revealed significant heterogeneity in temporal patterns for two biomarkers (Table 2). BNP showed the strongest exposure-related divergence (ΔAIC = 10.36, P = 0.002; R^2(interaction) = 0.131 vs R^2(main) = 0.128; 6,934 observations from 1,399 patients), followed by CK-MB (ΔAIC = 5.04, P = 0.019; R^2(interaction) = 0.042 vs R^2(main) = 0.041; 9,799 observations from 1,574 patients). In contrast, Myoglobin and Troponin showed comparable temporal trajectories regardless of PD-1 exposure after adjustment for covariates.

The marginal increase in R^2 values between the interaction and main-effect models indicates that incorporating time-by-exposure interactions modestly improved model fit, particularly for BNP, reflecting a distinct exposure-dependent evolution over time.

Discussion

Our study, leveraging a large real-world cohort of 2,427 lung cancer patients exposed to 82 targeted agents, provides one of the most comprehensive assessments to date of cardiotoxicity profiles across major therapeutic classes. Approximately 13% of patients experienced biomarker-defined cardiotoxicity. Among therapeutic classes, PD-1 inhibitors conferred the highest cardiotoxic risk, whereas EGFR inhibitors were associated with a comparatively lower incidence of cardiac events. The results further suggest that BNP and CK-MB, rather than troponin alone, may serve as sensitive early indicators of immune-related myocardial stress during PD-1 therapy. While previous studies have highlighted PD-1–related myocarditis (13), our data reveal a broader spectrum of subclinical myocardial stress, captured notably by BNP and CK-MB rather than troponin alone

Clinically, PD-1–based immune checkpoint inhibitors are among the agents most frequently implicated in immune-mediated myocarditis and are associated with substantial morbidity and mortality despite their low absolute incidence (14). Immune checkpoint blockade can trigger systemic immune activation that extends to cardiac tissues (15). PD-1 signaling is essential for restraining autoreactive T-cell responses and preserving myocardial immune tolerance; both cardiomyocytes and cardiac-resident immune cells rely on PD-1/PD-L1 interactions to limit cytotoxic activity (15). Inhibition of this pathway removes a key peripheral tolerance mechanism, enabling T-cell infiltration, proinflammatory cytokine release, and direct myocyte injury (16). Experimental models further support this biology: PD-1–deficient mice spontaneously develop autoimmune myocarditis, underscoring its nonredundant role in cardiac homeostasis (17). However, across the broad spectrum of targeted therapies, comparative risk estimates remain limited because most available evidence derives from case series or selected clinical-trial populations (18). Large real-world analyses are therefore needed to contextualize cardiotoxicity profiles across different therapeutic classes.

Although prior studies indicate that clinically overt ICI-associated myocarditis most commonly presents within the first 1–2 treatment cycles (19), our restricted cubic spline analysis revealed a nonlinear pattern with a steep rise in biomarker-defined cardiotoxicity up to approximately four administrations. This apparent shift likely reflects differences in case definition and patient populations. Unlike earlier reports focused on clinically adjudicated myocarditis—typically characterized by abrupt, early presentations (19)—our real-world cohort captures a broader spectrum of myocardial injury, including subclinical or attenuated phenotypes that may require multiple cycles of exposure before surpassing biomarker thresholds. The more

heterogeneous clinical characteristics of routine oncology populations, including older age, multimorbidity, and polypharmacy, may also contribute to the delayed inflection in risk (20). Therefore, the cycle-dependent pattern observed in our study should not be interpreted as contradicting prior evidence but rather as complementary, highlighting that early-onset toxicity dominates overt myocarditis, whereas cumulative or subclinical injury may manifest over several administrations. This pattern is consistent with an early phase of immune activation reported in mechanistic studies, in which PD-1 blockade enables rapid T-cell activation and clonal expansion (21); however, direct evidence linking cycle number to clonal kinetics is limited, and the observed inflection point more likely reflects cumulative subclinical injury in real-world settings.

The longitudinal biomarker trajectories further clarify the temporal heterogeneity of cardiac injury. BNP and CK-MB showed significant exposure-related divergence, whereas troponin remained largely stable over time. These differences likely reflect distinct biological pathways and timing of myocardial stress. BNP, secreted by ventricular myocytes in response to wall stretch, is an early and sensitive indicator of hemodynamic overload or diastolic dysfunction, often preceding structural injury (22). CK-MB, a cytosolic enzyme released during myocyte membrane permeability changes, represents a transitional stage of subclinical injury (23). In contrast, troponin elevation signifies frank myocyte necrosis and tends to appear later and transiently during acute myocarditis episodes (24). Although clinically overt ICI-associated myocarditis is characterized by acute necrotic injury and marked troponin release, such cases represent only a small and highly selected subset of the overall cardiotoxicity spectrum captured in published case series (25). In routine practice—particularly when systematic biomarker surveillance is applied—many PD-1–related cardiac abnormalities manifest instead as mild or asymptomatic elevations in markers of myocardial stress or membrane permeability rather than fulminant necrosis(26). Therefore, in a real-world population enriched for low-grade or evolving myocardial stress rather than catastrophic necrotic injury, sustained BNP and CK-MB changes with minimal troponin release are pathophysiologically consistent. Consequently, integrating multiple biomarkers with complementary temporal sensitivity may improve early detection of PD-1-related cardiac effects (27).

Limitations

Several limitations should be acknowledged. As a single-center retrospective analysis, residual confounding cannot be fully excluded(28). Cardiotoxicity was defined biochemically rather than by imaging, potentially

15   overestimating mild or transient injury; however, biomarker-based definitions improve sensitivity for early

16   stress detection and align with current cardio-oncology recommendations. Surveillance intensity differed

17   between groups, which may introduce detection bias (29).

Conclusions

- PD-1 inhibitors are independently associated with increased cardiotoxicity risk in lung cancer patients.
- The cardiotoxic risk of PD-1 therapy peaks around four treatment cycles.
- BNP and CK-MB trajectories capture early subclinical myocardial stress, whereas troponin remains stable, reflecting distinct temporal phases of cardiac injury.

Data Availability Statement

All data produced in the present study are available upon reasonable request to the authors.

Funding

All authors received support from the National Natural Science Foundation of China (Nos. U21A20341 and 82470394); the Shanghai Municipality Science and Technology Commission (Nos. 25Y12800500, 24DZ2202700, and 20Y11910500); the Shanghai Municipal Health Commission (No. 202440156); the Shanghai Academic/Technology Leader Program (No. 21XD1432100); the Basic–Clinical Collaborative Innovation Project from the Shanghai Immune Therapy Institute; and the Basic–Clinical Collaborative Innovation Project from the Shanghai Key Laboratory of Computational Chemistry and Nanomedicine (No. 2025ZYB-007).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Consent for publication

Not applicable.

Conflict of Interest Statement

No potential conflicts of interest were disclosed by the authors.

Clinical trial number

Not applicable.

Reference

1. Mahmood A, Reza M, Ali Heidarnejad m, Adel H, Samaneh R, Salar Hozhabri S, *et al.* Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer cell international **2023** doi 10.1186/s12935-023-02990-y.

2. Bin L, Juan J, Duancheng G, Zhonghua T, Xichun H. Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials. Cancers **2023** doi 10.3390/cancers15102858.

3. Joerg H. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature reviews Cardiology **2020** doi 10.1038/s41569-020-0348-1.

4. Panagiotis T, Panayotis KV, Evangelos O, Maria D, Paschalis K, Anastasios A, *et al.* Cancer Therapy-Related Cardiac Dysfunction: A Review of Current Trends in Epidemiology, Diagnosis, and Treatment. Biomedicines **2024** doi 10.3390/biomedicines12122914.

5. Li C, Huijuan D, Xinning G, Liheng Z, Meng J. Comprehensive review of non-invasive treatment related cardiovascular toxicity in breast cancer. iScience **2025** doi 10.1016/j.isci.2025.111759.

6. Victoria S, Katherine G, Michelle EB. Cancer Therapies and Cardiac Dysfunction. Heart failure **2022** doi 10.1201/9780429244544-36.

7. Yuwen H, Wanwen C, Junying C, Caiyin L, Chengzhi Z, Xing L. PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients. Journal of thoracic disease **2023** doi 10.21037/jtd-23-596.

8. Arvind KP, Eric KS, Juan Pablo A, İkizler TA, Edward G, Jonathan DB, *et al.* Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension (Dallas, Tex : 1979) **2017** doi 10.1161/hypertensionaha.117.10271.

9. Yunlong W, Qinggui Q, Xuan D, Wan M. EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring. Frontiers in oncology **2024** doi 10.3389/fonc.2024.1426796.

10. Yen Yi T, Václav P, Wai Hoong C, Stefanie HM, Spiros D, Alvina GL. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. The lancet Healthy longevity **2022** doi 10.1016/s2666-7568(22)00186-6.

11. Hasan K, Islam E, Emma F, Mary Claire OB, Dorak MT, Shereen NG. Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity:

are real-world studies the way forward? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners **2022** doi 10.1177/10781552221077417.

12. Adithya C, Laith A, Ning J, Carolyn JP, Ashish M. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Frontiers in immunology **2022** doi 10.3389/fimmu.2022.779691.

13. ML DP, E R, R Z, V E, G M. Immune Checkpoint Inhibitors and Cardiovascular Adverse Events. ESC heart failure **2025**;12(4):2404-16 doi 10.1002/ehf2.15281.

14. Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1/PD-L1 inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism. Frontiers in Pharmacology **2022**;13:835510.

15. Grabie N, Lichtman AH, Padera R. T cell checkpoint regulators in the heart. Cardiovascular research **2019**;115(5):869-77.

16. Huang S, Kang Y, Liu T, Xiong Y, Yang Z, Zhang Q. The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure. Frontiers in Immunology **2025**;16:1561968.

17. Liu S-Y, Huang W-C, Yeh H-I, Ko C-C, Shieh H-R, Hung C-L, *et al.* Sequential blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity—from case report to mouse model validation. Cancers **2019**;11(4):580.

18. Rhea IB, Oliveira GH. Cardiotoxicity of Novel Targeted Chemotherapeutic Agents. Curr Treat Options Cardiovasc Med **2018**;20(7):53 doi 10.1007/s11936-018-0649-4.

19. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc **2020**;9(2):e013757 doi 10.1161/jaha.119.013757.

20. Aggarwal P, Woolford SJ, Patel HP. Multi-morbidity and polypharmacy in older people: challenges and opportunities for clinical practice. Geriatrics **2020**;5(4):85.

21. Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, *et al.* Clonal replacement of tumor-specific T cells following PD-1 blockade. Nature medicine **2019**;25(8):1251-9.

22. Zhipeng C, Yuqing J, Bao-Li Z. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. International journal of molecular sciences **2019** doi 10.3390/ijms20081820.

23. Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, *et al.* Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. European heart journal **2005**;26(15):1494-8.

24. White HD. Pathobiology of Troponin Elevations[⁎]. JACC **2011**;57(24):2406-8 doi doi:10.1016/j.jacc.2011.01.029.

25. Douglas BJ, Justin MB, Margaret C, Spyridon C, Joshua MG, Yaomin X, *et al.* Fulminant Myocarditis with Combination Immune Checkpoint Blockade. The New England journal of medicine **2016** doi 10.1056/NEJMoa1609214.

26. Walid S, Amjad A-S, Rachel S, Binil Mathew J, Ismaell M, Alexander Y. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers **2021** doi 10.3390/cancers13205218.

27. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, *et al.* 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal **2022**;43(41):4229-361 doi 10.1093/eurheartj/ehac244.

28. Kim YR, Chung SW, Kim M-J, Choi W-M, Choi J, Lee D, *et al.* Limited generalizability of retrospective single-center cohort study in comparison to multicenter cohort study on prognosis of hepatocellular carcinoma. Journal of Hepatocellular Carcinoma **2024**:1235-49.

29. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. Jama **2011**;305(23):2462-3.

31
Figure 1. Study Flow and Analytical Framework
Flowchart summarizing cohort selection and analyses. Among 2,427 lung cancer patients treated with targeted therapies,
358 without cardiac biomarker data were excluded, yielding 2,069 for analysis. Patients were stratified into cardiotoxicity (n
= 326) and non-cardiotoxicity (n = 1,743) groups. Primary analysis compared cardiotoxicity risk across targeted therapy
classes. Secondary analyses included subgroup comparisons, nonlinear PD-1 exposure–response assessment, and
longitudinal cardiac biomarker trajectory modeling.

B

Subgroup	Target	Events/Total	HR (95% CI)	P value	P for interaction
No comorbidity	PD-1	60/380	1.97 (1.40-2.77)	<0.01	0.14
	EGFR	55/561	0.48 (0.34-0.69)	<0.01	0.34
	VEGF	85/500	1.75 (1.27-2.42)	<0.01	0.05
	OTHERS	27/132	2.76 (1.81-4.19)	<0.01	<0.01
Age <65 years	PD-1	29/183	1.38 (0.87-2.18)	0.18	0.03
	EGFR	32/261	0.52 (0.33-0.83)	<0.01	0.42
	VEGF	54/285	1.53 (1.01-2.34)	0.05	0.86
	OTHERS	16/68	2.47 (1.39-4.38)	<0.01	0.16
Age ≥65 years	PD-1	103/473	2.39 (1.81-3.16)	<0.01	0.03
	EGFR	79/602	0.50 (0.37-0.68)	<0.01	0.42
	VEGF	122/611	1.37 (1.05-1.79)	0.02	0.86
	OTHERS	28/162	1.71 (1.15-2.55)	<0.01	0.16
Male	PD-1	111/540	2.15 (1.63-2.82)	<0.01	0.58
	EGFR	52/368	0.53 (0.39-0.73)	<0.01	0.67
	VEGF	129/649	1.34 (1.02-1.75)	0.04	0.32
	OTHERS	28/140	1.93 (1.29-2.89)	<0.01	0.92
Female	PD-1	21/116	1.72 (1.04-2.83)	0.03	0.58
	EGFR	59/495	0.51 (0.33-0.77)	<0.01	0.67
	VEGF	47/247	1.67 (1.12-2.49)	0.01	0.32
	OTHERS	16/90	2.15 (1.24-3.72)	<0.01	0.92
With CVD history	PD-1	60/185	1.93 (1.35-2.75)	<0.01	0.26
	EGFR	52/225	0.61 (0.41-0.88)	<0.01	0.15
	VEGF	84/294	1.18 (0.85-1.65)	0.32	0.26
	OTHERS	14/63	1.35 (0.78-2.36)	0.29	0.02
Without CVD history	PD-1	72/471	2.06 (1.50-2.84)	<0.01	0.26
	EGFR	59/638	0.47 (0.34-0.66)	<0.01	0.15
	VEGF	92/602	1.61 (1.19-2.19)	<0.01	0.26
	OTHERS	30/167	2.68 (1.80-3.99)	<0.01	0.02

Hazard Ratio (HR): 0 0.5 1 2 3 4 5

Figure 2. Cardiovascular Risk Associated with Different Targeted Therapies Overall and by Patient Subgroups

Panel A shows overall hazard ratios (HRs) and 95% confidence intervals (CIs) for cardiovascular events associated with different

targeted therapies. **Panel B** presents subgroup analyses stratified by baseline comorbidities, age, sex, and cardiovascular disease

(CVD) history. All analyses were adjusted for age, sex, baseline CVD, diabetes, hypertension, hyperlipidemia, and cumulative

treatment cycles using multivariable Cox proportional hazards models. The vertical dashed line represents HR = 1.0 (no difference

in risk). P for interaction tests whether treatment effects differ significantly across subgroups.

Abbreviations: PD-1, programmed cell death protein 1; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial

growth factor; BCR-ABL, breakpoint cluster region-Abelson; ALK, anaplastic lymphoma kinase; HER2, human epidermal

growth factor receptor 2; CVD, cardiovascular disease.

Figure 3. Non-linear Association Between PD-1 Inhibitor Exposure Frequency and Cardiotoxicity Risk

The hazard ratio (HR) and 95% confidence intervals (CI) are plotted on the y-axis against the cumulative number of PD-1

doses on the x-axis. A significant non-linear association was observed (P for nonlinearity = 0.002).

Temporal trajectories of cardiac biomarkers
Stratified by PD-1 exposure (adjusted for covariates)

PD-1 exposure — Unexposed — Exposed

Figure 4. Temporal trajectories of cardiac biomarkers by PD-1 inhibitor exposure.
Predicted longitudinal trajectories over 2500 days after treatment initiation are shown for BNP, CK-MB, myoglobin, and troponin. PD-1–exposed patients exhibited marked late-phase increases in BNP and myoglobin, moderate elevations in CK-MB, and minimal changes in troponin. Divergence between exposure groups emerged after approximately 1500 days, indicating potential cumulative cardiotoxic effects associated with prolonged PD-1 inhibitor therapy. Shaded areas represent 95% confidence intervals.

Table 1. Baseline characteristics.

Variables	No cardiotoxicity (n = 1,743)	Cardiotoxicity (n = 326)	*P*
Follow-up period (days)	621.00 [287.50, 1,053.00]	89.50 [24.00, 285.75]	<0.01
Male gender	1073 (61.6)	221 (67.8)	0.04
Age	69.00 [62.00, 74.00]	69.00 [63.00, 74.75]	0.10
Medical history			
Hyperlipidemia	97 (5.6)	15 (4.6)	0.57
Hypertension	339 (19.4)	123 (37.7)	<0.01
Myocardial infarction	54 (3.1)	36 (11.0)	<0.01
Arrhythmia	46 (2.6)	25 (7.7)	<0.01
Heart failure	12 (0.7)	16 (4.9)	<0.01
Thrombosis	136 (7.8)	22 (6.7)	0.59
Diabetes	178 (10.2)	49 (15.0)	0.01
Targeted therapy exposure			
PD-1	524 (30.1)	132 (40.5)	<0.01
EGFR	752 (43.1)	111 (34.0)	<0.01
VEGF	720 (41.3)	176 (54.0)	<0.01
OTHERS	186 (10.7)	44 (13.5)	0.16
BCR-ABL	14 (0.8)	7 (2.1)	0.05
ALK	81 (4.6)	19 (5.8)	0.44
HER2	22 (1.3)	4 (1.2)	1.00
Targeted therapy administrations			
PD-1	3.00 [2.00, 7.00]	5.50 [3.00, 10.00]	<0.01
EGFR	7.00 [2.00, 17.00]	17.00 [7.50, 29.00]	<0.01
VEGF	4.00 [1.00, 8.00]	5.00 [2.00, 12.00]	<0.01
OTHERS	2.00 [1.00, 5.00]	5.00 [3.00, 10.00]	<0.01
BCR-ABL	10.00 [4.25, 13.00]	12.00 [9.00, 13.00]	0.548
ALK	6.00 [2.00, 12.00]	14.00 [8.00, 21.00]	<0.01
HER2	6.00 [2.25, 10.50]	7.00 [2.50, 14.00]	0.92
Cardiac biomarker monitoring			
BNP	1490 (85.5)	324 (99.4)	<0.01
Troponin	1448 (83.1)	308 (94.5)	<0.01
Myo	1376 (78.9)	314 (96.3)	<0.01
CK-MB	1589 (91.2)	321 (98.5)	<0.01
Cardiac biomarker measurements			
BNP	3.00 [1.00, 6.00]	8.00 [4.00, 15.00]	<0.01
Troponin	2.00 [1.00, 5.00]	6.00 [3.00, 10.00]	<0.01
Myo	3.00 [1.00, 6.00]	6.50 [4.00, 12.00]	<0.01
CK-MB	4.00 [2.00, 9.00]	10.00 [6.00, 17.00]	<0.01

Data are presented as n (%) for categorical variables and median [IQR] for continuous variables. P-values calculated using chi-square test for categorical variables and Mann-Whitney U test for continuous variables. Only patients who had at least one administration of targeted therapy and at least one cardiac biomarker measurement were included to avoid zero-inflated counts.

Biomarker	No. of observations	No. of patients with cardiotoxicity	ΔAIC	*P*-value	R^2 (interaction)	R^2 (main)
BNP	6934	1399	10.36	**0.002**	0.131	0.128
CK-MB	9799	1574	5.04	**0.0192**	0.042	0.041
Myoglobin	6414	1308	1.88	0.0641	0.096	0.095
Troponin	3589	1094	1.08	0.0896	0.013	0.012

Table 2. Model comparison results assessing the association between PD-1 inhibitor exposure and longitudinal trajectories of four cardiac biomarkers. *ΔAIC* represents the reduction in Akaike Information Criterion when including the PD-1 × time interaction term, indicating model improvement. *R^2 (interaction)* and *R^2 (main)* denote the proportion of variance explained by the interaction and main-effect models, respectively. *No. of observations* indicates total biomarker measurements; *No. of patients with cardiotoxicity* refers to individuals who developed cardiotoxicity and contributed at least one biomarker record. Significance levels: *$P < 0.05$* (*), *$P < 0.01$* (**), ns = not significant.